Eli Lilly Forecasts 15% Gain to $1,400 Backed by $27B Expansion and $8.7B Mounjaro Sales
LLY•Analysts predict Lilly's stock to reach $1,400 by end-2026, representing a 15% gain from current levels, driven by Foundayo rollout, $27B in manufacturing expansion, direct pharmacy distribution and Medicare pricing agreements. The stock recently hit record highs as obesity and diabetes portfolio drives confidence, with Mounjaro posting $8.662B in Q1 sales, up 125% year-over-year, though competition and rich valuation pose risks.
1. Price Prediction and Expansion
Analysts set a $1,400 year-end target for Lilly’s stock, implying a 15% gain from July levels. This outlook rests on the launch of oral obesity drug Foundayo, a $27 billion manufacturing buildout, direct pharmacy distribution and negotiated Medicare pricing deals.
2. Portfolio Performance and Record Highs
Shares reached fresh record highs as confidence mounts in Lilly’s obesity and diabetes offerings. Mounjaro generated $8.662 billion in first-quarter 2026 revenue, up 125% year-over-year, underscoring the drug’s blockbuster status.
3. Competitive and Valuation Risks
Despite bullish forecasts, Lilly faces stiff competition from Novo Nordisk’s injectable rivals and must justify a premium valuation. Execution risks around drug launches and expansion projects could temper upside if milestones slip.
